Neuronetics, Inc. (STIM)
NASDAQ: STIM · IEX Real-Time Price · USD
3.810
+0.310 (8.86%)
At close: May 3, 2024, 4:00 PM
3.720
-0.090 (-2.36%)
After-hours: May 3, 2024, 5:23 PM EDT
Neuronetics Revenue
In the year 2023, Neuronetics had annual revenue of $71.35M with 9.42% growth. Revenue in the quarter ending December 31, 2023 was $20.31M with 11.63% year-over-year growth.
Revenue (ttm)
$71.35M
Revenue Growth
+9.42%
P/S Ratio
1.59
Revenue / Employee
$351,468
Employees
203
Market Cap
113.37M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 71.35M | 6.14M | 9.42% |
Dec 31, 2022 | 65.21M | 9.89M | 17.89% |
Dec 31, 2021 | 55.31M | 6.07M | 12.32% |
Dec 31, 2020 | 49.24M | -13.41M | -21.41% |
Dec 31, 2019 | 62.66M | 9.88M | 18.72% |
Dec 31, 2018 | 52.78M | 12.34M | 30.53% |
Dec 31, 2017 | 40.43M | 6.21M | 18.13% |
Dec 31, 2016 | 34.23M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sangamo Therapeutics | 176.23M |
OptiNose | 70.99M |
KORU Medical Systems | 29.32M |
Adagene | 18.11M |
Abeona Therapeutics | 3.50M |
aTyr Pharma | 353.00K |
Zentek | 25.27K |
GlycoMimetics | 10.00K |
STIM News
- 1 day ago - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month - GlobeNewsWire
- 11 days ago - Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call - GlobeNewsWire
- 24 days ago - New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital - GlobeNewsWire
- 5 weeks ago - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression - GlobeNewsWire
- 2 months ago - Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network - GlobeNewsWire
- 2 months ago - Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results - GlobeNewsWire